In non-small-cell lung cancer (NSCLC), elevated ABCC2 expression in cisplatin-resistant A549 cells promotes drug resistance by facilitating drug efflux and inhibiting apoptosis [27]. Here, ABCC2 is linked to non-small cell lung carcinoma.